IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/19/2021 | $10.00 | Buy | EF Hutton |
4 - HCW Biologics Inc. (0001828673) (Issuer)
EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00
8-K - HCW Biologics Inc. (0001828673) (Filer)
8-K - HCW Biologics Inc. (0001828673) (Filer)
10-Q - HCW Biologics Inc. (0001828673) (Filer)
8-K - HCW Biologics Inc. (0001828673) (Filer)
8-K - HCW Biologics Inc. (0001828673) (Filer)
8-K/A - HCW Biologics Inc. (0001828673) (Filer)
10-Q - HCW Biologics Inc. (0001828673) (Filer)
8-K - HCW Biologics Inc. (0001828673) (Filer)
8-K - HCW Biologics Inc. (0001828673) (Filer)
8-K - HCW Biologics Inc. (0001828673) (Filer)
MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022. "We have achieved several milestones in the first half of 2022, and some important pieces of our strategic plan have fallen into place. First, we are now a clinical-stage company, with the entry of our lead product candidate, HCW9218, into the clinic in a
MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. "We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging," stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. "HCW Biologics is developing immunotherapeutics that do not treat a single indica
MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced above market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an
HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules HCW Biologics to receive upfront payment of $7 million and is eligible to receive additional milestone payments and double-digit royalties on future product sales MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the ear
MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2024. Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "In the third quarter 2024, the Company expanded our product portfolio and possible disease indications that may be treated with our immunotherapeutic compounds, consisting of compounds constructed us
MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2024. Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "We reached a critical milestone recently that has profound implications for the future of our Company -- we successfully reached a settlement agreement for an arbitration that created an overhang that hampered our
MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2024. Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "We reached an important clinical development milestone in the first quarter of 2024. Enrollment was completed in two ongoing clinical trials to evaluate HCW9218 in solid tumors. We are encouraged by the number
MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023. Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu
MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2023. A human data readout from the ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors was presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") by Melissa A. Geller, M.D., M.S.,
Showed HCW9218 clinical safety and tumor response endpointsfor 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug cand
MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota. The poster will be presented by Melissa A. Geller, M.D., M.S., Professor and Division
MIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City. On September 12, 2023, the Company will be meeting individual investors in person at the conference venue, the Lotte New York Palace Hotel in New York. In addition, a pre-recorded, virtual Company update will be available on demand beginning at 7:00 a.m. EDT on September 11, 2023 for
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023. Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu
HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(0.20) per share. This is a 42.86 percent decrease over losses of $(0.14) per share from the same period last year. The company reported $1.13 million in sales this quarter. This is a 2.59K percent increase over sales of $41.88 thousand the same period last year.
- SEC Filing
Gainers PaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ:ALLR) stock increased by 55.84% to $3.58. The company's market cap stands at $1.6 million. HCW Biologics (NASDAQ:HCWB) shares increased by 20.77% to $1.86. The market value of their outstanding shares is at $70.3 million. Portage Biotech (NASDAQ:PRTG) stock rose 17.6% to $0.59. The company's market cap stands at $11.6 million. PepGen (NASDAQ:PEPG) shares rose 16.75% to $14.84. The company's market cap stands at $480.1 million. Akanda (NASDAQ:AKAN) stock increased by 15.82% to $0.17. The
HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. The company reported quarterly sales of $1.341 million which beat the analyst consensus estimate of $900.000 thousand by 49.00 percent. This is a 0.07 percent decrease over sales of $1.342 million the same period last year.
-8-K
Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results. The company posted a quarterly net loss of $10.1 million, inclusive of $3.2 million in non-cash items, or 12 cents per share for the fourth quarter, versus a year-ago net loss of $14.3 million, inclusive of $6.0 million in non-cash items, or 18 cents per share for the year-ago period. Anavex Life Sciences shares fell 10% to $6.35 on Monday. Here are some other stocks moving in today's mid-day session. Gainers RedHill Biopharma Ltd. (NASDAQ:RDHL) shares climbed 125% to $0.7063 after the company announced the FDA has granted five years' mark
Gainers Senti Biosciences (NASDAQ:SNTI) shares rose 14.5% to $0.52 during Thursday's after-market session. The market value of their outstanding shares is at $23.0 million. MSP Recovery (NASDAQ:LIFW) shares increased by 10.41% to $0.06. At the close, MSP Recovery's trading volume reached 525.6K shares. This is 45.2% of its average volume over the last 100 days. The company's market cap stands at $20.4 million. HCW Biologics (NASDAQ:HCWB) stock moved upwards by 8.45% to $2.31. The company's market cap stands at $82.9 million. Tempest Therapeutics (NASDAQ:TPST) stock increased by 8.28% to $0.54. The market value of their outstanding shares is at $7.1 million. TransCode Therapeutics (NASDA